Trial record 1 of 1 for:
4630-03
Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05054725 |
|
Recruitment Status :
Active, not recruiting
First Posted : September 23, 2021
Last Update Posted : April 3, 2023
|
Sponsor:
Revolution Medicines, Inc.
Collaborators:
Sanofi
Amgen
Information provided by (Responsible Party):
Revolution Medicines, Inc.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Active, not recruiting |
|---|---|
| Estimated Primary Completion Date : | September 30, 2023 |
| Estimated Study Completion Date : | March 3, 2024 |